Irina V. Ganshina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irina V. Ganshina has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Anna V. Kirillova
N.I. Pirogov Russian National Research Medical University
3 shared publications - Dmitry E. Yurov
The Russian National Research Medical University named after N.I. Pirogov
3 shared publications - Elena V. Markina
N.I. Pirogov Russian National Research Medical University
3 shared publications - German V. Kukushkin
Pirogov Russian National Research Medical University
3 shared publications - Gyulnara O. Dibirova
Pirogov Russian National Research Medical University
3 shared publications - Maksim Leonidovich Maksimov
FSBEI CPE Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia, FSAEI HE Pirogov Russian National Research Medical University of the Ministry of Health of Russia
3 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (2) , 139-149
Influenza virus infection affects the efficacy of the treatment of dyslipidemia in mice with a polyisoprenoid-based drug
Objective. To evaluate how influenza infection affects the hypolipidemic effect of a novel combined drug – Prenophytol based on polyisoprenoids (sodium polyprenyl phosphate and beta-sitosterol) in mice with experimental dyslipidemia. Materials and methods. In BALB/c mice with experimentally induced dyslipidemia, the impact of Prenophytol on lipid metabolism parameters was assessed. Currently the drug is at the stage of clinical trials (Roszdravnadzor's permission to conduct clinical trials No. 362 dated 08/14/2025). A subset of animals was infected with influenza A/California/07/2009 (H1N1) virus. Results. Administration of the drug to dyslipidemia mice resulted in a significant reduction in total cholesterol, triglycerides, and LDL levels, along with a significant increase in HDL. However, in the presence of influenza infection, the hypolipidemic effect of Prenophytol was markedly attenuated: only cholesterol levels decreased significantly, whereas changes in triglycerides, LDL, and HDL did not reach statistical significance. Conclusions. Influenza infection diminishes the therapeutic efficacy of the Prenophytol in the treatment of dyslipidemia. These findings indicate that concomitant viral infections must be taken into account when designing dyslipidemia treatment regimens and conducting clinical trials of this drug.
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 71 (2) , 139-149
Open AccessInfluenza virus infection affects the efficacy of the treatment of dyslipidemia in mice with a polyisoprenoid-based drug
Objective. To evaluate how influenza infection affects the hypolipidemic effect of a novel combined drug – Prenophytol based on polyisoprenoids (sodium polyprenyl phosphate and beta-sitosterol) in mice with experimental dyslipidemia. Materials and methods. In BALB/c mice with experimentally induced dyslipidemia, the impact of Prenophytol on lipid metabolism parameters was assessed. Currently the drug is at the stage of clinical trials (Roszdravnadzor's permission to conduct clinical trials No. 362 dated 08/14/2025). A subset of animals was infected with influenza A/California/07/2009 (H1N1) virus. Results. Administration of the drug to dyslipidemia mice resulted in a significant reduction in total cholesterol, triglycerides, and LDL levels, along with a significant increase in HDL. However, in the presence of influenza infection, the hypolipidemic effect of Prenophytol was markedly attenuated: only cholesterol levels decreased significantly, whereas changes in triglycerides, LDL, and HDL did not reach statistical significance. Conclusions. Influenza infection diminishes the therapeutic efficacy of the Prenophytol in the treatment of dyslipidemia. These findings indicate that concomitant viral infections must be taken into account when designing dyslipidemia treatment regimens and conducting clinical trials of this drug.
- 23 July 2021
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 27 (2) , 175-182
Antibiotic treatment failure
This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.
- 23 July 2021
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 27 (2) , 175-182
Antibiotic treatment failure
This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.
- 15 May 2021
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 27 (3) , 273-280
Vaccine safety for COVID-19 prevention
BACKGROUND: In 2021, the Uppsala Monitoring Center of the World Health Organization included 52 vaccines for coronavirus disease-2019 (COVID-19) prevention in the international database, VigiBase, and almost immediately, this group of medicines (drugs) took the lead in the increased rate of reported adverse reactions (ARs). AIM: This study aimed to review the case reports of ARs from COVID-19 vaccines in the VigiBase database. MATERIALS AND METHODS: Statistical analysis of cases that describe ARs in the international pharmacovigilance VigiBase database was performed. RESULTS: On May 12, 2021, the VigiBase database included 26,099,906 reports that describe AR cases on drugs, including 585,744 reports of AR on vaccines for COVID-19 prevention. Serious ARs after immunization with these vaccines were registered in 31.5% of reports, including 0.9% fatal and 1.3% life-threatening. Headache (37.1% of reports), pyrexia (31.1%), chills (23.2%), and fatigue (22.7%) were most frequently recorded. CONCLUSIONS: More data are required to confirm the association between the COVID-19 vaccines and the increased risk of ARs following their use.
- 15 May 2021
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 27 (3) , 273-280
Vaccine safety for COVID-19 prevention
BACKGROUND: In 2021, the Uppsala Monitoring Center of the World Health Organization included 52 vaccines for coronavirus disease-2019 (COVID-19) prevention in the international database, VigiBase, and almost immediately, this group of medicines (drugs) took the lead in the increased rate of reported adverse reactions (ARs). AIM: This study aimed to review the case reports of ARs from COVID-19 vaccines in the VigiBase database. MATERIALS AND METHODS: Statistical analysis of cases that describe ARs in the international pharmacovigilance VigiBase database was performed. RESULTS: On May 12, 2021, the VigiBase database included 26,099,906 reports that describe AR cases on drugs, including 585,744 reports of AR on vaccines for COVID-19 prevention. Serious ARs after immunization with these vaccines were registered in 31.5% of reports, including 0.9% fatal and 1.3% life-threatening. Headache (37.1% of reports), pyrexia (31.1%), chills (23.2%), and fatigue (22.7%) were most frequently recorded. CONCLUSIONS: More data are required to confirm the association between the COVID-19 vaccines and the increased risk of ARs following their use.
- Open Access
- 16 June 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (2) , 57-64
Drug Safety for Children — International Monitoring Data for 50 Years
Безопасность применения лекарственных средств у детей — данные международного мониторинга за 50 лет
- 16 June 2019
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 7 (2) , 57-64
Open AccessDrug Safety for Children — International Monitoring Data for 50 Years
Безопасность применения лекарственных средств у детей — данные международного мониторинга за 50 лет